Crossmark

Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study

Published Online: 2019-04-30

Published Print: 2019-05-01

Authors

Wolf, Anne

Langmann, Thomas https://orcid.org/0000-0001-6826-529X
License Information

Text and Data Mining valid from 2019-04-30

Version of Record valid from 2019-04-30
More Information

Article History

First Online: 30 April 2019

Conflict of interest

: TL serves in advisory boards for Bayer, Novartis, and Roche that develop drugs for retinal degenerative and neovascular diseases.

Document is current